BRVE

Braveheart Bio, Inc. - Common Stock (BRVE)

About Braveheart Bio, Inc. - Common Stock (BRVE)

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Details

Daily high
$19.46
Daily low
$17.79
Price at open
$19.46
52 Week High
$32.00
52 Week Low
$16.70
Market cap
1.8B
Dividend yield
-
Volume
971,320
Avg. volume
425,781
P/E ratio
--

Braveheart Bio, Inc. - Common Stock News

Details

Daily high
$19.46
Daily low
$17.79
Price at open
$19.46
52 Week High
$32.00
52 Week Low
$16.70
Market cap
1.8B
Dividend yield
-
Volume
971,320
Avg. volume
425,781
P/E ratio
--